Member Info for LiveLongnProsper

@jdt1990, cheers

Ha, yes 'AffXell' = AffyXell ! (can't blame spell check)

Yes @Richob and @jdt1990, this ‘Expansion of Partnership with Daewoong’ is possibly part of the answer (I hope only part, as neutralising Affimers potentially too important for an exclusive license) …
https://www.londonstockexchange.com/news-article/AVCT/expanded-partnership-with-daewoong-pharmaceutical/14632432
The AffXell work to develop “a novel class of mesenchymal stem cell (MSC) treatments that are engineered to also produce Affimer therapies in the patient at the site of action” was being discussed on this board last weekend.
Getting Affimers into the human body, either directly, or via their creation for ‘engineered stem cells’, would be (I’ll say it again) truly ‘game changing’.
Also discussed was this clinical trial being undertaken by Daewoong in Indonesia …
https://clinicaltrials.gov/ct2/show/study/NCT04535856
This is for ‘allogeneic mesenchymal stem cells’ (product designated DW-MSC) in patients with Covid-19. Though there is no mention of AffXell, the stem cells being ‘engineered’, or of Affimers. Looks like this trial is safety focused (2 dosing regimens), but also with some expectation of clinical improvement in patients.
But otherwise, it has indeed ‘gone very quiet’.
GLA

Looks like mid-Sept 2020 when LFT ‘direction change happened.
RNS 07/09/20 ELISA test – “Avacta remains focused on the much larger opportunity of the saliva-based coronavirus antigen rapid test that we are developing with Cytiva and which is now in the process of technology transfer to our manufacturing partners.”
RNS 30/09/20 BAMS – no mention of Cytiva. So, by RNS 23/11/20 Test Update, looks like Avacta had been working on a revised test for ~2 months. Would have thought it should be working, tested, validated, approved, etc. by now?
Last 4 RNS’s updated footnotes …
“Avacta's Diagnostics Division works with partners world-wide to develop bespoke Affimer reagents for third party products. The Company is also developing an in-house pipeline of Affimer-based diagnostic assays including the AffiDXTM SARS-CoV-2 Lateral Flow Rapid Antigen Test and a BAMSTM SARS-CoV-2 Assay in partnership with Adeptrix Inc.”.
The LFT has a trade-marked name - the AffiDXTM SARS-CoV-2 Lateral Flow Rapid Antigen Test.
Prior to that (up to and including 07/01/2021 Licence Agreement with POINT Biopharma Inc.) the RNS’s were only mentioning that …
“Avacta's diagnostics business unit works with partners world-wide to develop Affimer reagents for evaluation by those third parties with the objective of establishing royalty bearing license deals. The Company is also developing a small in-house pipeline of Affimer-based diagnostic assays for licensing”.
The Avacta web site was recently updated to show SARS-Cov-2 tests ‘front and centre’ (well, now ‘front and right hand side’).
Affimers work, for example Affimer-based SARS-CoV-2 BAMS assay is for sale (OK, research only) …
https://www.adeptrix.com/store#!/SARS-CoV-2-S1-Glycoprotein-Assay/p/234586062
GLA

Yes, no change to avacta test piece, just some of other pages not working from home page, eg news. Could mean some 'construction'work.
GLA

As discussed yesterday and today, avacta.com has been updated for improved presentation and new information. Just now looks like medusa19.com not fully working (could just be me)?
Not getting conspiratorial, but suspect Web Dev's know more about what's going on than most.
GLA

Yep, but take out the nominee accounts (us PI's) represented by HL and similar.
GLA

The SARS-Cov-2 tab on the Avacta.com home page is now on the right hand side!
I think, or am I imagining? What is the significance?
GLA

Dido is really, really, struggling. Has so little grasp of anything - wider context, numbers, etc. Hiding behind a QA process, just parroting the few KPI's she can remember, embarrassing.
GLA

https://parliamentlive.tv/Event/Index/fdc89ad8-3182-46ea-b723-e71bb1480245
Link to Dido live.
GLA

09:00 today, discussion about various aspects of testing, worth a listen though will be nothing particularly new to 'regulars' here. One thing I thought was interesting though was the stated number of LFT's being used - 350,000 per day, including a rather dismissive mention of a 'few' antibody tests. What was BBI capacity, ~2m per week? Well that's going to be used up straight away, Innova stocks running out soon, oh, and nothing left over for Ursula and friends! Gonna need more capacity.
GLA

Just to add, the trial is NCT04535856 and the product DW-MSC. The protocol involves 2 dose amounts and seems focused on safety. But the patients have covid and some therapeutic value is suggested. One way or another there just might be more to this than meets the eye?
GLA

RNS of 29/07/20 is key. Neutralizing Affimers being picked up by AffyXell. As discussed over last 2 days, question is is the Daewoong trial in Indonesia using mesenchymal stem cells modified to generate Affimers? Affimers in the human body would be massive, game changing, etc.
GLA

Maybe (though possibly not a vegetable)?
Very low volume over last hour or so, anyone see if order being filled?
GLA

"Simon also has first-hand experience of the biotech industry having worked as a scientist at Peptide Therapeutics (Acambis). By profession Simon is a chemist, obtaining his credentials at Imperial College, Cambridge University and Stanford University. "
So ideal for 'communicating' with Sir Al!
GLA

Yes, synergy here I think.
https://www.pointbiopharma.com/science/canseek
canSEEK™ is a promising technology for use in next generation radiopharmaceuticals, as it may allow for the precision treatment of a variety of solid tumour cancers
POINT Radioligands seem to be well established, but what if Avacta technology (pre|CISION™, Affimers) are better at the targeting job (FAP expressing cancer cells) than canSEEK?
GLA

Very nice, Avacta named.
GLA

@ Energyshares, hope they are directly connected. Affimers in the human body would be much bigger than LFT. But will take that as well!
GLA

This is the link I posted earlier (update on post from @Richob on 12/12/2020) ...
https://clinicaltrials.gov/ct2/show/study/NCT04535856
Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients (DW-MSC).
Being carried out in Indonesia. Completed Jan 14th, record updated Jan 25th. Drug: allogeneic mesenchymal stem cell (DW-MSC). Doesn't say anything about being modified for Affimer production, but is being tested on Covid19 patients.
GLA

@Energyshares, thanks for replying. Yes, saw that, also posted earlier about the Daewoong ct in Indonesia. Would like to see the definite link between DWP710, AffyXell and Affimers. Not clear (to me anyway) from article posted by yourself or ct link I posted. Very happy to be enlightened.
GLA